Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Stem Cell Research

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 90 articles:
HTML format
Text format



Single Articles


    August 2018
  1. DELSING MALMBERG E, Johansson Alm S, Nicklasson M, Lazarevic V, et al
    Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
    Leuk Lymphoma. 2018 Aug 2:1-9. doi: 10.1080/10428194.2018.1485910.
    PubMed     Text format     Abstract available


    July 2018
  2. KAMEL AM, El-Fishawi S, Rasekh EO, Radwan ER, et al
    Variability of contribution of vitamin D receptor gene polymorphisms to outcome of HLA-matched sibling allogeneic bone marrow transplantation.
    Leuk Lymphoma. 2018 Jul 4:1-10. doi: 10.1080/10428194.2018.1459608.
    PubMed     Text format     Abstract available


  3. ADRIANZEN HERRERA D, Ayyappan S, Jasra S, Kornblum N, et al
    Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant - a case series.
    Leuk Lymphoma. 2018 Jul 3:1-7. doi: 10.1080/10428194.2018.1474523.
    PubMed     Text format     Abstract available


  4. ROMERO S, Montoro J, Guinot M, Almenar L, et al
    Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1474462.
    PubMed     Text format     Abstract available


    June 2018
  5. PERMPALUNG N, Mahoney MV, McCoy C, Atsawarungruangkit A, et al
    Clinical characteristics and treatment outcomes among respiratory syncytial virus (RSV)-infected hematologic malignancy and hematopoietic stem cell transplant recipients receiving palivizumab.
    Leuk Lymphoma. 2018 Jun 27:1-7. doi: 10.1080/10428194.2018.1468896.
    PubMed     Text format     Abstract available


  6. CAPRIA S, Pepe S, Trisolini SM, Testi AM, et al
    Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.
    Leuk Lymphoma. 2018 Jun 26:1-3. doi: 10.1080/10428194.2018.1468895.
    PubMed     Text format    


    May 2018
  7. REICH-SLOTKY R, Makhani SS, Vasovic LV, Pearse RN, et al
    Comparison of time to engraftment between autologous patients receiving washed versus non-washed cryopreserved peripheral blood stem cell products.
    Leuk Lymphoma. 2018 May 23:1-7. doi: 10.1080/10428194.2018.1455975.
    PubMed     Text format     Abstract available


  8. ALDERUCCIO JP, Mackrides N, Chapman JR, Vega F, et al
    Rapid complete response to blinatumomab as a successful bridge to allogeneic stem cell transplantation in a case of refractory Richter syndrome.
    Leuk Lymphoma. 2018 May 10:1-4. doi: 10.1080/10428194.2018.1461862.
    PubMed     Text format    


  9. MORI Y, Yoshimoto G, Yuda JI, Hayashi M, et al
    Previous exposure to bortezomib is linked to a lower risk of engraftment syndrome after autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 May 9:1-3. doi: 10.1080/10428194.2018.1466295.
    PubMed     Text format    


  10. SPINA F, Radice T, De Philippis C, Soldarini M, et al
    Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Leuk Lymphoma. 2018 May 1:1-9. doi: 10.1080/10428194.2018.1459607.
    PubMed     Text format     Abstract available


    April 2018
  11. KOBULNICKY DJ, Sabo RT, Sharma S, Shubar Ali AS, et al
    The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-9. doi: 10.1080/10428194.2018.1452216.
    PubMed     Text format     Abstract available


  12. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed     Text format    


    March 2018
  13. ANDREINI A, Zampieri N, Costantini C, Malerba G, et al
    Chronic graft versus host disease is associated with erectile dysfunction in allogeneic hematopoietic stem cell transplant patients: a single-center experience.
    Leuk Lymphoma. 2018 Mar 21:1-4. doi: 10.1080/10428194.2018.1443338.
    PubMed     Text format    


  14. POLVERELLI N, Malagola M, Turra A, Skert C, et al
    Comparative study on ATG-thymoglobulin versus ATG-fresenius for the graft-versus-host disease (GVHD) prophylaxis in allogeneic stem cell transplantation from matched unrelated donor: a single-centre experience over the contemporary years.
    Leuk Lymphoma. 2018 Mar 12:1-6. doi: 10.1080/10428194.2018.1439584.
    PubMed     Text format    


    February 2018
  15. ICHII M, Oritani K, Murase M, Komatsu K, et al
    Molecular targeting of inosine-5'-monophosphate dehydrogenase by FF-10501 promotes erythropoiesis via ROS/MAPK pathway.
    Leuk Lymphoma. 2018;59:448-459.
    PubMed     Text format     Abstract available


    January 2018
  16. CAO L, Koh LP, Linn YC
    Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib.
    Leuk Lymphoma. 2018 Jan 18:1-3. doi: 10.1080/10428194.2017.1421759.
    PubMed     Text format    


  17. BLUME R, Rempel E, Manta L, Saeed BR, et al
    The molecular signature of AML with increased ALDH activity suggests a stem cell origin.
    Leuk Lymphoma. 2018 Jan 16:1-10. doi: 10.1080/10428194.2017.1422862.
    PubMed     Text format     Abstract available


  18. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.
    PubMed     Text format    


  19. CHEN A, Chao K, Rodriguez L, Munday W, et al
    Toxic epidermal necrolysis versus cutaneous Graft-Versus-Host Disease in a hematopoietic stem cell transplant recipient: the role of elafin.
    Leuk Lymphoma. 2018 Jan 11:1-3. doi: 10.1080/10428194.2017.1422867.
    PubMed     Text format    


    December 2017
  20. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Text format     Abstract available


  21. TANDRA A, Covut F, Cooper B, Creger R, et al
    Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1390234.
    PubMed     Text format     Abstract available


    November 2017
  22. GIULINO-ROTH L, O'Donohue T, Chen Z, Trippett TM, et al
    Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.
    Leuk Lymphoma. 2017 Nov 29:1-10. doi: 10.1080/10428194.2017.1403601.
    PubMed     Text format     Abstract available


  23. SASAKI K, Mori Y, Yoshimoto G, Sakoda T, et al
    Successful treatment of Ph ALL with hematopoietic stem cell transplantation from the same HLA-haploidentical related donor of previous liver transplantation.
    Leuk Lymphoma. 2017 Nov 22:1-3. doi: 10.1080/10428194.2017.1403021.
    PubMed     Text format    


    October 2017
  24. STEVENS H, Raj K, Ashby M, Grigg A, et al
    Allogeneic stem cell transplantation as a risk factor for recurrent melanoma.
    Leuk Lymphoma. 2017 Oct 31:1-3. doi: 10.1080/10428194.2017.1393670.
    PubMed     Text format    


  25. GREIL C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, et al
    Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1393673.
    PubMed     Text format    


  26. PATEL P, Oh AL, Koshy M, Sweiss K, et al
    A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m2 and total marrow irradiation (TMI) in patients with relapsed/refractory multiple myeloma.
    Leuk Lymphoma. 2017 Oct 25:1-6. doi: 10.1080/10428194.2017.1390231.
    PubMed     Text format     Abstract available


  27. ZAGADAILOV EA, Corman S, Chirikov V, Johnson C, et al
    Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1382698.
    PubMed     Text format     Abstract available


  28. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Text format     Abstract available


  29. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Text format     Abstract available


  30. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Text format     Abstract available


    September 2017
  31. ZINTER MS, Melton A, Sabnis AJ, Dvorak CC, et al
    Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
    Leuk Lymphoma. 2017 Sep 28:1-4. doi: 10.1080/10428194.2017.1382697.
    PubMed     Text format    


  32. MAZIARZ RT, Hao Y, Guerin A, Gauthier G, et al
    Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Sep 21:1-10. doi: 10.1080/10428194.2017.1375100.
    PubMed     Text format     Abstract available


  33. ARBOE B, Halgren Olsen M, Duun-Henriksen AK, Gorlov JS, et al
    Prolonged hospitalization, primary refractory disease, performance status and age are prognostic factors for survival in patients with diffuse large B-cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Sep 4:1-10. doi: 10.1080/10428194.2017.1369061.
    PubMed     Text format     Abstract available


    August 2017
  34. WINTER A, Rybicki L, Shah SN, Jagadeesh D, et al
    Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2017 Aug 30:1-7. doi: 10.1080/10428194.2017.1369065.
    PubMed     Text format     Abstract available


  35. DHERE V, Edelman S, Waller EK, Langston A, et al
    Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Aug 7:1-7. doi: 10.1080/10428194.2017.1361027.
    PubMed     Text format     Abstract available


    July 2017
  36. SANTIAGO V, Lazaryan A, McClune B, McKenna RW, et al
    Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
    Leuk Lymphoma. 2017 Jul 21:1-9. doi: 10.1080/10428194.2017.1352094.
    PubMed     Text format     Abstract available


  37. SIMONETTA F, Masouridi-Levrat S, Beauverd Y, Tsopra O, et al
    Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2017 Jul 6:1-11. doi: 10.1080/10428194.2017.1344844.
    PubMed     Text format     Abstract available


  38. HAMPRAS SS, Locke FL, Chavez JC, Patel NS, et al
    Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1342822.
    PubMed     Text format     Abstract available


    June 2017
  39. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed     Text format    


  40. MICHALLET M, Sobh M, Garban F, Bulabois CE, et al
    Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study.
    Leuk Lymphoma. 2017 Jun 7:1-9. doi: 10.1080/10428194.2017.1334120.
    PubMed     Text format     Abstract available


  41. GAUTAM A, Zhu Y, Ma E, Lee SY, et al
    Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
    Leuk Lymphoma. 2017 Jun 5:1-8. doi: 10.1080/10428194.2017.1324160.
    PubMed     Text format     Abstract available


  42. LI Z, Wang Y, Wang J, Zhang J, et al
    Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
    Leuk Lymphoma. 2017 Jun 2:1-8. doi: 10.1080/10428194.2017.1330467.
    PubMed     Text format     Abstract available


  43. MILONE G, Martino M, Leotta S, Spadaro A, et al
    Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma.
    Leuk Lymphoma. 2017 Jun 2:1-7. doi: 10.1080/10428194.2017.1324161.
    PubMed     Text format     Abstract available


  44. HAZAR V, Kesik V, Karasu GT, Ozturk G, et al
    Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry.
    Leuk Lymphoma. 2017 Jun 2:1-12. doi: 10.1080/10428194.2017.1330472.
    PubMed     Text format     Abstract available


    May 2017
  45. XIAO X, Huang H, Chen J, Jiang Y, et al
    Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1317096.
    PubMed     Text format    


  46. SKAMENE T, Crump M, Savage KJ, Reiman T, et al
    Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
    Leuk Lymphoma. 2017 May 15:1-9. doi: 10.1080/10428194.2017.1312379.
    PubMed     Text format     Abstract available


  47. DEBUS L, Vigouroux S, Gargallo G, Adiko F, et al
    No adverse effect of granulocyte colony-stimulating factor during the peri-implantation period of an unrecognized pregnancy in a donor of peripheral blood stem cells.
    Leuk Lymphoma. 2017 May 9:1-2. doi: 10.1080/10428194.2017.1312389.
    PubMed     Text format    


    March 2017
  48. EL CHEIKH J, Massoud R, Haffar B, Fares E, et al
    Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307362.
    PubMed     Text format    


  49. ANGUITA-COMPAGNON AT, Dibarrart MT, Paredes L, Araos D, et al
    Peripheral blood stem cell mobilization with a single dose of PEG-filgrastim in patients with multiple myeloma previously treated with radiotherapy.
    Leuk Lymphoma. 2017 Mar 16:1-4. doi: 10.1080/10428194.2017.1300895.
    PubMed     Text format    


  50. COCITO F, Mangiacavalli S, Bernasconi P, Colombo AA, et al
    Long-term control of extensive refractory chronic graft versus host disease in a multiple myeloma relapsing after allogeneic transplant. A case report.
    Leuk Lymphoma. 2017 Mar 13:1-2. doi: 10.1080/10428194.2017.1300890.
    PubMed     Text format    


    February 2017
  51. NICOL C, Henry C, Couturier MA, Delepine P, et al
    Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only.
    Leuk Lymphoma. 2017 Feb 7:1-3. doi: 10.1080/10428194.2017.1285025.
    PubMed     Text format    


    January 2017
  52. GREIL C, Kiote-Schmidt C, Fink G, Ihorst G, et al
    Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
    Leuk Lymphoma. 2017 Jan 13:1-13. doi: 10.1080/10428194.2016.1271946.
    PubMed     Text format     Abstract available


  53. PETERSON LF, Lo MC, Liu Y, Gianolla D, et al
    Induction of p53 suppresses chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jan 13:1-14. doi: 10.1080/10428194.2016.1272682.
    PubMed     Text format     Abstract available


  54. ISHII H, Konuma T, Kato S, Oiwa-Monna M, et al
    Impact of hematogones on the long-term outcomes of single-unit cord blood transplantation for adult patients.
    Leuk Lymphoma. 2017;58:118-126.
    PubMed     Text format     Abstract available


    December 2016
  55. HOGAN JJ, Loren AW, Denker MG, Mangan JK, et al
    Edema with hypoalbuminemia as a rare manifestation of chronic graft versus host disease after allogeneic hematopoietic cell transplant.
    Leuk Lymphoma. 2016 Dec 21:1-3. doi: 10.1080/10428194.2016.1270451.
    PubMed     Text format    


    November 2016
  56. SHINOHARA A, Inamoto Y, Kurosawa S, Hiramoto N, et al
    High non-relapse mortality and low relapse incidence in gender-mismatched allogeneic hematopoietic stem cell transplantation from a parous female donor with a male child.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  57. CHOE H, Martin P
    Frontline autologous stem cell transplant for high-risk follicular lymphoma: forever elusive?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    October 2016
  58. PHILLIPS AA
    Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  59. STETTLER J, Novak U, Baerlocher GM, Seipel K, et al
    Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  60. OGUNNIYI A, Rodriguez M, Devlin S, Adel N, et al
    Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  61. WANG W, Foerner E, Buss E, Jauch A, et al
    Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  62. ZHAO XS, Qin YZ, Liu YR, Chang YJ, et al
    The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    September 2016
  63. GUPTA R, Kumar L, Dahiya M, Mathur N, et al
    Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  64. TOKUNAGA M, Uto H, Takeuchi S, Nakano N, et al
    Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    August 2016
  65. SORIGUE M, Sancho JM, Morgades M, Moreno M, et al
    Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  66. SHARMA P, Shinde SS, Damlaj M, Hefazi Rorghabeh M, et al
    Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  67. KOLDEHOFF M, Ross SR, Duhrsen U, Beelen DW, et al
    Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  68. ASLAN A, Aras T, Ozdemir E
    Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  69. MONTORO J, Sanz J, Sanz GF, Sanz MA, et al
    Advances in haploidentical stem cell transplantation for hematologic malignancies.
    Leuk Lymphoma. 2016;57:1766-75.
    PubMed     Text format     Abstract available


    July 2016
  70. BALASSA K, Krahling T, Remenyi P, Batai A, et al
    Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    June 2016
  71. BRAMMER JE, Khouri I, Marin D, Ledesma C, et al
    Stem cell transplantation outcomes in lymphoblastic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  72. MAYER S, Pastores SM, Riedel E, Maloy M, et al
    Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  73. BEAUVERD Y, Cortes B, Masouye I, Chalandon Y, et al
    Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  74. BAETZ T, Chen BE, Couban S, Tom Kouroukis C, et al
    Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    May 2016
  75. SHIPOUNOVA IN, Petinati NA, Bigildeev AE, Drize NJ, et al
    Alterations of the bone marrow stromal microenvironment in adult patients with acute myeloid and lymphoblastic leukemias before and after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  76. ISIDORI A, Christofides A, Visani G
    Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  77. MICHALLET M, Sobh M, Labussiere H, Lombard C, et al
    Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  78. FIALA MA, Slade M, Wang S, Park S, et al
    The impact of diabetes mellitus and other comorbidities on hematopoietic stem cell collection and hematologic recovery post-transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  79. THOMAS CM, Ippoliti C, Roboz GJ, Feldman E, et al
    Clofarabine as a bridge to hematopoietic stem cell transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  80. ITONAGA H, Taguchi J, Taguchi M, Taniguchi H, et al
    Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  81. CHIEW MY, Boo NY, Voon K, Cheong SK, et al
    Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  82. GRAIN A, Sirvent A, Strullu M, Francoise M, et al
    Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bo
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  83. VON TRESCKOW B, Morschhauser F, Szer J, Eichenauer DA, et al
    Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    March 2016
  84. BELTON A, Xian L, Huso T, Koo M, et al
    STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    January 2016
  85. VALTOLA J, Varmavuo V, Ropponen A, Selander T, et al
    Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  86. SANFORD D, Garcia-Manero G, Jorgensen J, Konoplev S, et al
    CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    December 2015
  87. GARG S, Shanmukhaiah C, Ghosh K, Madkaikar M, et al
    Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    August 2015
  88. FUNGPIPAT P, Sophonphan J, Sosothikul D, Suppipat K, et al
    Redefine Clinical Risk Classification in Children with Precursor B Cell Acute Lymphoblastic Leukemia using Pretreatment Absolute Lymphocyte Count.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  89. ILIFF A, Divine C, Diaz F, Aljitawi O, et al
    Adequacy of Peripheral Blood Stem Cell Mobilization in Patients with Relapsed B Cell Non Hodgkin Lymphoma Treated with Bendamustine.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    March 2015
  90. KOLDEHOFF M, Lindemann M, Opalka B, Bauer S, et al
    Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stem Cell Research is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: